BlackRock Fund Advisors’s Tvardi Therapeutics TVRD Stock Holding History

BlackRock Fund Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$6.43M	Sell	19,237 -7,264	-27%	-$2.33M	﹤0.01%	2813
2016 Q3	$7.97M	Buy	26,501 +1,397	+6%	+$303K	﹤0.01%	2591
2016 Q2	$4.35M	Buy	25,104 +929	+4%	+$202K	﹤0.01%	2875
2016 Q1	$5.41M	Buy	24,175 +477	+2%	+$142K	﹤0.01%	2702
2015 Q4	$14.4M	Sell	23,698 -1,384	-6%	-$760K	﹤0.01%	2235
2015 Q3	$12.9M	Buy	25,082 +4,585	+22%	+$3.07M	﹤0.01%	2253
2015 Q2	$8.96M	Buy	20,497 +8,112	+65%	+$3.14M	﹤0.01%	2575
2015 Q1	$4.48M	Buy	12,385 +791	+7%	+$299K	﹤0.01%	2900
2014 Q4	$4.16M	Buy	11,594 +7,974	+220%	+$2.57M	﹤0.01%	2974
2014 Q3	$1.09M	Sell	3,620 -149	-4%	-$61.2K	﹤0.01%	3191
2014 Q2	$2.31M	Sell	3,769 -351	-9%	-$189K	﹤0.01%	3115
2014 Q1	$2.76M	Buy	+4,120	New	+$2.44M	﹤0.01%	3083

Other funds holding TVRD

RCP

Rho Capital Partners New York $20.4M AUM

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EAM

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Fund Advisors's TVRD Position: Q4 2016 in Review

BlackRock Fund Advisors reduced its Tvardi Therapeutics (TVRD) stake by 27% in Q4 2016, selling an estimated $2.33M and leaving 19,237 shares worth $6.43M. The position accounts for ﹤0.01% of the portfolio, ranked #2813.

BlackRock Fund Advisors first reported a position in TVRD in Q1 2014 and has held it in 12 quarters since. The position peaked at $14.4M in Q4 2015. 101 funds tracked by Wall St. Rank hold TVRD as of Q4 2016.

BlackRock Fund Advisors held 19,237 shares of Tvardi Therapeutics worth $6.43M as of Q4 2016.
BlackRock Fund Advisors sold 7,264 Tvardi Therapeutics shares in Q4 2016, an estimated $2.33M.
Tvardi Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2813 holding.
BlackRock Fund Advisors first reported a position in Tvardi Therapeutics in Q1 2014 and has held it in 12 quarters since.
BlackRock Fund Advisors's Tvardi Therapeutics position peaked at $14.4M in Q4 2015.
101 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.